Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 28, Issue 3, 2010, Pages 487-492

  Lee, Young Joo ^a   Cho, Byoung Chul ^a   Jee, Sun Ha ^a   Moon, Jin Wook ^a   Kim, Se Kyu ^a   Chang, Joon ^a   Chung, Kyung Young ^a   Park, In Kyu ^a   Choi, Sung Ho ^a   Kim, Joo Hang ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; NUCLEOTIDE; TOBACCO SMOKE;

ADULT; ADULTHOOD; AGED; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EXON; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOLOGY; HOUSEHOLD; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SEX RATIO; SMOKING; TREATMENT RESPONSE; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PASSIVE SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOBACCO SMOKE POLLUTION;

EID: 75749139367     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.5480     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
2. Toh C, Wong E, Lim W, et al: The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: A retrospective analysis. Chest 126:1750-1756, 2004
3. Grsel G, Levent E, Oztrk C, et al: Hospital based survey of lung cancer in Turkey, a developing country, where smoking is highly prevalent. Lung Cancer 21:127-132, 1998
4. Lee C, Kang KH, Koh Y, et al: Characteristics of lung cancer in Korea, 1997. Lung Cancer 30:15-22, 2000
5. Boffetta P, Jrvholm B, Brennan P, et al: Incidence of lung cancer in a large cohort of non-smoking men from Sweden. Int J Cancer 94:591-593, 2001
6. Thun MJ, Henley SJ, Burns D, et al: Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 98:691-699, 2006
7. Hashimoto T, Tokuchi Y, Hayashi M, et al: Different subtypes of human lung adenocarcinoma caused by different etiological factors: Evidence from p53 mutational spectra. Am J Pathol 157:2133-2141, 2000
8. Wong MP, Lam WK, Wang E, et al: Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. Cancer Res 62:4464-4468, 2002
9. Hainaut P, Olivier M, Pfeifer GP: TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: Lessons from the IARC TP53 mutation database. Mutagenesis 16:551-553, 2001; author reply 555, 2001
10. Toyooka S, Tsuda T, Gazdar AF: The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 21:229-239, 2003
11. Toyooka S, Maruyama R, Toyooka KO, et al: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103:153-160, 2003
12. Heelan RT, Rusch V, Zakowski M, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
13. Shepherd FA, Pereira JR, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
14. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
15. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
16. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
17. Ahn M, Park B, Ahn JS, et al: Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 14:3860-3866, 2008
18. Tomizawa Y, Iijima H, Sunaga N, et al: Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11:6816-6822, 2005
19. Hsieh R, Lim K, Kuo H, et al: Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128: 317-321, 2005
20. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
21. Paez JG, Jnne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
22. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173, 2005
23. Pham D, Kris MG, Riely GJ, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24:1700-1704, 2006
24. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004
25. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525-1530, 2001
26. Gazdar AF, Shigematsu H, Herz J, et al: Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers? Trends Mol Med 10:481-486, 2004
27. Vineis P, Alavanja M, Buffler P, et al: Tobacco and cancer: Recent epidemiological evidence. J Natl Cancer Inst 96:99-106, 2004
28. Vineis P, Airoldi L, Veglia F, et al: Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 330:277, 2005
29. Stayner L, Bena J, Sasco AJ, et al: Lung cancer risk and workplace exposure to environmental tobacco smoke. Am J Public Health 97:545-551, 2007
30. Han S, Kim T, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501, 2005
31. Husgafvel-Pursiainen K, Boffetta P, Kannio A, et al: p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res 60:2906-2911, 2000
32. Lodovici M, Caldini S, Luceri C, et al: Active and passive smoking and lifestyle determinants of 8-oxo-7,8-dihydro-2′-deoxyguanosine levels in human leukocyte DNA. Cancer epidemiology biomarkers & prevention 14:2975-2977, 2005
33. Collier AC, Dandge SD, Woodrow JE, et al: Differences in DNA-damage in non-smoking men and women exposed to environmental tobacco smoke (ETS). Toxicol Lett 158:10-19, 2005
34. Boffetta P, Ahrens W, Nyberg F, et al: Exposure to environmental tobacco smoke and risk of adenocarcinoma of the lung. Int J Cancer 83:635-639, 1999
35. Hammond SK, Sorensen G, Youngstrom R, et al: Occupational exposure to environmental tobacco smoke. JAMA 274:956-960, 1995